Cloud4C Recognized as Microsoft Azure Expert Managed Service Provider
17.12.2019 15:00:00 EET | Business Wire | Press release
Cloud4C, a Global Cloud Managed Services Provider, announced that it has achieved Microsoft Azure Expert Managed Services Provider status from Microsoft.
Cloud4C is one of the latest Cloud Managed Services Providers globally to be recognized as an Azure Expert MSP. The Azure Expert MSP recognition credits a cloud solution provider who has proven expertise and differentiation in the marketplace showcasing capabilities across Azure services in helping customers navigate cloud landscape efficiently.
Cloud4C was recognized as an Azure Expert MSP based on the company’s expertise across datacenter modernization services, cloud migration and managed services, SAP hosting services, business continuity, advisory services, advanced security management techniques, and constant improvement methodologies for Azure clients.
Cloud4C will continue to deepen its collaboration with Microsoft to deliver end-to-end services to enable enterprises to migrate and manage workloads on Azure. With this collaboration, Cloud4C’s Migration factory built for Azure will help enterprises in modernizing their applications and Databases seamlessly to the cloud. With specialized skills for OpenSource databases like PostgreSQL, MariaDB, MySQL, etc., customized commercial database management services are enabling enterprises to transform on a cost-effective model while providing flexibility and agility to the clients’ IT eco-system.
Sridhar Pinnapureddy, Founder & CEO at Cloud4C, said, "Our latest achievement is a testament to the depth of our Microsoft expertise and capabilities. We are committed to delivering value-based business outcomes by staying true to our ‘Total Ownership Philosophy’ and helping enterprises seamlessly deploy and manage workloads on Microsoft Azure. Our deep technical expertise as a certified Azure Expert MSP allows customers to focus on their core business functions and trust us with managing the intricacies of cloud.”
Gavriella Schuster, Corporate Vice President, One Commercial Partner, Microsoft Corp. said, “We developed the Microsoft Azure Expert Managed Service Provider program to validate and recognize our most accomplished and qualified partners to drive growth for customers. With this recognition, Cloud4C has demonstrated their expertise and commitment to deliver premium managed services on Azure.”
With 600+ Azure Certified professionals and serving 3500+ enterprises on cloud, Cloud4C is enabling customers to achieve seamless digital cloud journeys with specialized solution offering across SAP core Banking, E-commerce, Big Data & analytics, Cyber security, Open Source Databases, AI/ML, Hybrid Cloud, Devops, Automation, IOT, Blockchain and App Modernization on Azure.
ABOUT CLOUD4C
Cloud4C is a preferred Cloud Evolution Partner to 3500 enterprises including 60 of Fortune 500 companies’. Cloud4C has over 1800 certified experts with presence across 25 countries managing mission critical workloads across public, private and hybrid cloud platforms. Cloud4C has delivered 1 billion managed services hours with experience in migrating and managing more than 25000 applications and databases on to cloud powered by AIOps and 24X7 ML enabled monitoring.
For more information, log onto https://www.cloud4c.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191217005363/en/
Contact information
Samuel Varghese | Cloud4C | press@cloud4c.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release
The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 15:48:00 EEST | Press release
Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong engagement across asset classes, geographies and user activity: Users from more than 180 different countries $38.4 billion in cumul
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom